Sugi Predict

Sugi Predict / Compounds / SCHEMBL1980294

SCHEMBL1980294

SCHEMBL1980294

Oc1cccc2c1C1(CC1)CO2

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ADAMTS4 O75173 1/20 0.32
▸ ALDH1A1 P00352 1/20 0.32
▸ EGFR P00533 1/20 0.32
▸ CA1 P00915 1/20 0.32
▸ CA2 P00918 1/20 0.32
▸ LMNA P02545 1/20 0.32
▸ FYN P06241 1/20 0.32
▸ MMP2 P08253 1/20 0.32
▸ MMP9 P14780 1/20 0.32
▸ HPGD P15428 1/20 0.32
▸ ALOX15 P16050 1/20 0.32
▸ MMP8 P22894 1/20 0.32
▸ CA6 P23280 1/20 0.32
▸ CDK2 P24941 1/20 0.32
▸ MMP12 P39900 1/20 0.32
▸ RECQL P46063 1/20 0.32
▸ HSD17B10 Q99714 1/20 0.32
▸ TDP1 Q9NUW8 1/20 0.32
▸ ADAMTS5 Q9UNA0 1/20 0.32
▸ AKT1 P31749 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29913397 1.00 ADAMTS4 (0.32) ADAMTS4ALDH1A1EGFRCA1CA2
SCHEMBL9904685 0.82 ITGB2 (0.38) ADAMTS4ALDH1A1EGFRCA1CA2
SCHEMBL21262971 0.79 ALDH1A1 (0.35) ADAMTS4ALDH1A1EGFRCA1CA2
SCHEMBL1764717 0.76 CNR1 (0.34) ADAMTS4ALDH1A1EGFRCA1CA2
SCHEMBL21116508 0.72 HTR1A (0.39) ALDH1A1CA1CA2HSD17B10TDP1
SCHEMBL31304774 0.70 PLK1 (0.41) —
SCHEMBL18199055 0.69 TMEM97 (0.32) —
SCHEMBL16661511 0.69 ITGB2 (0.37) LMNAAKT1ITGB2ICAM1ITGAL
SCHEMBL9904847 0.69 BCL2L1 (0.33) ADAMTS4ALDH1A1EGFRCA1CA2
SCHEMBL18025155 0.68 TSHR (0.36) CA1CA2LMNAALOX15HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 113 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160251340-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS GLAXOSMITHKLINE S.P.A. (IT) 2016-09-01 — — US claimed
EP-2649066-B1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS AUTIFONY THERAPEUTICS LTD (GB) 2015-10-21 — — EP claimed
EP-2649066-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS Autifony Therapeutics Limited (GB) 2013-10-16 — — EP claimed
US-20130267510-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS AUTIFONY THERAPEUTICS LIMITED (GB) 2013-10-10 — — US claimed
WO-2012076877-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS AUTIFONY THERAPEUTICS LIMITED (GB) 2012-06-14 — — WO claimed
US-20250304564-A1 NOVEL KV3 MODULATORS AUTIFONY THERAPEUTICS LTD (GB) 2025-10-02 — — US disclosed
US-12358901-B2 KV3 modulators AUTIFONY THERAPEUTICS LIMITED (GB) 2025-07-15 — — US disclosed
US-20240327406-A1 POTASSIUM CHANNEL MODULATORS AUTIFONY THERAPEUTICS LIMITED (GB) 2024-10-03 — — US disclosed
EP-3867247-B1 NOVEL COMPOUNDS AUTIFONY THERAPEUTICS LTD (GB) 2024-07-24 — — EP disclosed
EP-4384504-A1 POTASSIUM CHANNEL MODULATORS Autifony Therapeutics Limited (GB) 2024-06-19 — — EP disclosed
CN-117751119-A Potassium channel modulators 奥蒂福尼疗法有限公司 2024-03-22 — — CN disclosed
US-20230124087-A1 KV3 ENHANCERS FOR THE TREATMENT OF COGNITIVE DISORDERS HOFFMANN-LA ROCHE INC. (US) 2023-04-20 — — US disclosed
US-20120289526-A1 IMIDAZOLIDINEDIONE DERIVATIVES AUTIFONY THERAPEUTICS LIMITED (GB) 2012-11-15 — — US disclosed
US-20120289526-A1 IMIDAZOLIDINEDIONE DERIVATIVES AUTIFONY THERAPEUTICS LIMITED (GB) 2012-11-15 — — US disclosed
US-20120289526-A1 IMIDAZOLIDINEDIONE DERIVATIVES AUTIFONY THERAPEUTICS LIMITED (GB) 2012-11-15 — — US disclosed
EP-2509961-A1 IMIDAZOLIDINEDIONE DERIVATIVES Autifony Therapeutics Limited (GB) 2012-10-17 — — EP disclosed
WO-2012076877-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS AUTIFONY THERAPEUTICS LIMITED (GB) 2012-06-14 — — WO disclosed
WO-2012076877-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS AUTIFONY THERAPEUTICS LIMITED (GB) 2012-06-14 — — WO disclosed
WO-2011069951-A1 IMIDAZOLIDINEDIONE DERIVATIVES GLAXO GROUP LIMITED (GB) 2011-06-16 — — WO disclosed
WO-2011069951-A1 IMIDAZOLIDINEDIONE DERIVATIVES GLAXO GROUP LIMITED (GB) 2011-06-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12358901-B2 KV3 modulators KCNN3, KCNA3, KCNH3 ADAMTS4 4561/4885ALDH1A1 3109/4885EGFR 3926/4885
US-20240327406-A1 POTASSIUM CHANNEL MODULATORS KCNJ2, KCNN2, KCNN1 ADAMTS4 4192/4885ALDH1A1 2895/4885EGFR 4452/4885
US-20160251340-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS KCNA3, KCND3, KCNN3 ADAMTS4 3031/4885ALDH1A1 1789/4885EGFR 4817/4885
US-20230124087-A1 KV3 ENHANCERS FOR THE TREATMENT OF COGNITIVE DISORDERS KCNN3, KCNA4, KCNA3 ADAMTS4 4380/4885ALDH1A1 2760/4885EGFR 3786/4885
US-20120289526-A1 IMIDAZOLIDINEDIONE DERIVATIVES KCND3, KCNK3, KCNA3 ADAMTS4 3893/4885ALDH1A1 462/4885EGFR 3264/4885
US-20130267510-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS KCNA3, KCND3, KCNN3 ADAMTS4 3031/4885ALDH1A1 1789/4885EGFR 4817/4885
US-20250304564-A1 NOVEL KV3 MODULATORS KCNN3, KCNA3, KCND3 ADAMTS4 4501/4885ALDH1A1 3250/4885EGFR 4159/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.